BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ: NASDAQ:AMRX), a U.S.-based global pharmaceutical company, has announced the FDA approval of its New Drug Application for Pyridostigmine Bromide Extended-Release (PB ER) Tablets USP 105 mg. The once-daily tablet is designed as a pretreatment for protection against the lethal effects of soman nerve agent poisoning.
Developed with the support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), the PB ER tablets utilize Amneal’s GRANDE® drug delivery technology, which allows for a sustained 24-hour release of the drug. This new formulation is intended to replace the current pyridostigmine bromide product, which requires administration every eight hours, potentially improving compliance among U.S. Armed Services members and allies.
The PB ER 105 mg tablets were developed under a U.S. government agreement and represent the second NDA approval for Amneal this year, following a recent nod for a Parkinson’s disease medication. Co-CEOs Chirag and Chintu Patel expressed pride in supporting the U.S. military with this new therapy, highlighting Amneal's innovative product development capabilities.
Serious adverse reactions reported during the use of the product include breathing difficulties, dizziness, and loss of consciousness, with other observed adverse reactions such as dysmenorrhea, nosebleeds, reduced vision in one eye, and decreased tactile sensitivity.
Amneal, headquartered in Bridgewater, NJ, develops, manufactures, and distributes a diverse portfolio of over 280 generic and specialty pharmaceuticals. The company focuses on complex product categories and therapeutic areas, including central nervous system and endocrine disorders, through its Generics and Specialty segments, and serves the U.S. federal government, retail, and institutional markets through its AvKARE segment.
The information in this announcement is based on a press release statement and does not necessarily reflect the official policy or position of the Department of Defense or the U.S. Government. Amneal's forward-looking statements are subject to risks and uncertainties, as detailed in the company's filings with the Securities and Exchange Commission.
In other recent news, Amneal Pharmaceuticals has seen significant developments in its product portfolio and financial performance. The company has formed strategic partnerships with Metsera, according to Truist Securities, and launched CREXONT®, a novel treatment for Parkinson's disease. Moreover, Amneal has received FDA approval for BORUZU, an oncology drug for multiple myeloma and mantle cell lymphoma, and its generic propofol, addressing a chronic shortage of this essential anesthetic. This growth has been reflected in its Q2 revenues, which increased by 17% to reach $702 million, leading to an upward revision of its full-year guidance for 2024. JPMorgan upgraded Amneal's stock from Underweight to Neutral, following these strong performances. These recent developments highlight Amneal's strategic focus on complex generics and biosimilars, as well as its commitment to growth and market expansion.
InvestingPro Insights
Amneal Pharmaceuticals' recent FDA approval for its new drug application aligns with the company's positive financial trajectory. According to InvestingPro data, Amneal's revenue growth stands at 12.37% for the last twelve months as of Q2 2024, with an even more impressive quarterly revenue growth of 17.15% in Q2 2024. This growth is likely bolstered by the company's innovative product developments, such as the newly approved PB ER tablets.
InvestingPro Tips highlight that Amneal's net income is expected to grow this year, and analysts predict the company will be profitable. This outlook is particularly significant given the company's recent product approvals and its focus on complex product categories.
The company's stock has shown remarkable performance, with a one-year price total return of 147.26% as of the latest data. This strong return, coupled with the fact that the stock is trading near its 52-week high (95.87% of the high), suggests investor confidence in Amneal's strategic direction and growth potential.
For readers interested in a deeper analysis, InvestingPro offers 11 additional tips for Amneal Pharmaceuticals, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.